Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HW201877 Phase 1 Study in Healthy Volunteers
NCT07373457Phase 1Recruiting
- Sponsor
- Humanwell Healthcare Group Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in inflammatory bowel disease (IBD) comparing HW201877 capsules with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events at Day 5. Started Jun 2025; status: recruiting.
02
Drugs
HW201877
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07373457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07373457.